Nasdaq
$5.84▲ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $533.6MShares out 91.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 2d agoAfter-hours26.10.23 05:018-KKey event#●●●
GYRE THERAPEUTICS, INC.
Gyre Therapeutics entered into new employment agreements with CEO Dr. Ying Luo and CFO Thomas Eastling on October 16, 2026. The CEO will receive an annual base salary of $500,000 with a $150,000 target bonus for 2026, while the CFO will receive an annual base salary of $339,066 with a $70,000 target bonus for 2026. The agreements include provisions for severance payments and accelerated vesting of equity awards upon termination.…more
$5.84+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.1Pre-market26.09.01 22:008-KKey event
GYRE THERAPEUTICS, INC.
Gyre Therapeutics released an updated corporate presentation on September 1, 2026, detailing its protein degrader platform and pipeline progress. The company provided a total revenue guidance of $100.5 million to $111 million for ETUARY in 2026 and plans to submit IND applications and initiate Phase 1 clinical trials for CG923308 and CG620953 in the first quarter of 2027.…more
$5.84+0.09%vs prev closeView filingShare - 8.26Pre-market26.08.26 22:008-KKey event
GYRE THERAPEUTICS, INC.
Gyre Therapeutics released an updated corporate presentation on August 26, 2026. The company is leveraging its commercial platform and R&D capabilities in China to advance its Targeted Protein Degrader (TPD) and Degrader Antibody-Conjugate (DAC) pipelines, with plans to submit INDs and initiate Phase 1 trials for lead candidates CG923308 and CG620953 in the first quarter of 2027.…more
$5.84+0.09%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:33#●●●
Gyre Therapeutics Signs Employment Agreement For CEO and CFO
Gyre Therapeutics has entered into new employment agreements to retain its current CEO and CFO. This move ensures leadership continuity but does not represent a material financial change for the company.…more
$5.84+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.7Pre-market26.08.07 20:00
●●●●●●●● ●●●●● ●●●●●●
자이어 테라퓨틱스는 2분기 매출 2,910만 달러를 기록하며 연간 가이던스를 유지했습니다. 최근 컬젠 인수를 통해 단백질 분해제 파이프라인을 확보하고 신약 후보물질 F351의 임상 및 개발에 속도를 내고 있습니다.…more
$5.84+0.09%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report